Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of chronic & infectious disease in children
3.2.1.2 Increasing birth rate
3.2.1.3 Growing research & development activities for vaccine development
3.2.1.4 Rising government initiatives and funding
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulations for the approval of vaccines in developed nations
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)
5.1 Key trends
5.2 Monovalent vaccines
5.3 Multivalent vaccines
Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Million)
6.1 Key trends
6.2 Live attenuated vaccines
6.3 Inactivated vaccines
6.4 Toxoid vaccines
6.5 Conjugate vaccines
6.6 Other technologies
Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Million)
7.1 Key trends
7.2 Influenza
7.3 Human papilloma virus
7.4 Measles, mumps, and rubella
7.5 Polio
7.6 Pneumococcal disease
7.7 Diphtheria, pertussis, and tetanus
7.8 Other indications
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Million)
8.1 Key trends
8.2 Public
8.3 Private
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Astellas Pharma, Inc.
10.2 AstraZeneca Plc
10.3 CSL Limited
10.4 Daiichi Sankyo Company Limited
10.5 Emergent BioSolutions, Inc,
10.6 GlaxoSmithKline Plc
10.7 Grifol SA
10.8 Meissa Vaccines, Inc.
10.9 Merck & Co. Inc.
10.10 Panacea Biotec
10.11 Pfizer, Inc.
10.12 Sanofi SA
10.13 Serum Institute of India
10.14 Takeda Pharmaceutical Industries Limited
